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Abstract
Clostridium difficile infections (CDIs) are frequent in hospitals, but also seem to increase in the community. Here, we aim to determine the
incidence of CDI in general practice and to evaluate current testing algorithms for CDI. Three Dutch laboratories tested all unformed faeces
(12 714) for C. difficile when diagnostic testing (for any enteric pathogen) was requested by a general practitioner (GP). Additionally, a nested
case-control study was initiated, including 152 CDI patients and 304 age and sex-matched controls. Patients were compared using weighted
multivariable logistic regression.One hundred and ninety-four samples (1.5%)were positive forC. difficile (incidence 0.67/10 000 patient years).
This incidencewas comparable to that of Salmonella spp. Comparedwith diarrhoeal controls, CDIwas associatedwithmore severe complaints,
underlying diseases, antibiotic use and prior hospitalization. In our study, GPs requested a test for C. difficile in 7% of the stool samples, thereby
detecting 40% of all CDIs. Dutch national recommendations advise testing for C. difficilewhen prior antibiotic use or hospitalization is present
(18% of samples). If these recommendations were followed, 61% of all CDIs would have been detected. In conclusion, C. difficile is relatively
frequent in general practice. Currently, testing for C. difficile is rare and only 40% of CDI in general practice is detected. Following
recommendations that are based on traditional risk factors for CDI, would improve detection of CDI.
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Introduction
Clostridium difficile infection (CDI) is a common cause of
hospital-acquired diarrhoea. Elderly patients with underlying
diseases and recent antibiotic therapy are primarily affected,
resulting in prolonged hospitalization and excess mortality [1].
Recently, CDI was reported as an emerging disease outside
healthcare facilities [2]. Currently, more than a quarter of all
CDI is estimated to be acquired in the community [3]. In
contrast to nosocomial CDI, patients in the community are
younger, antibiotics are less frequently used and routes of
exposure are often unknown. Consequently, over a third of
these patients have no known risk factors for CDI [4,5]. This
makes recognition of CDI problematic, especially because
C. difficile is not widely tested for in general practitioners’
practices [6].
In 2009 a guideline was introduced in the UK, stating that all
cases of diarrhoea among patients aged ≥2 years in the
community should be tested for C. difficile unless good clinical
or epidemiological reasons not to are present [7]. Diarrhoea is
common in general practice, reaching incidences of 200 per
10 000 person years [8,9], which makes comprehensive testing
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costly. Consequently, the UK guideline was modified in 2012
and advised testing of all diarrhoeal samples of elderly patients
or patients with risk factors [10]. In most countries, including
the Netherlands and the USA, guidelines for general practi-
tioners still state that C. difficile should be suspected in patients
with a recent hospitalization or antibiotic use [11,12], which
may result in missed diagnoses.
Although the need to characterize patients with CDI in
the community is high, few studies focused on clinical
presentation and additional characteristics of this patient
group [5,13]. Additionally, studies often select diagnosed (and
therefore recognized) patients only. Therefore, we decided
to describe the occurrence of CDI in a laboratory-based
cohort study, testing for C. difficile irrespective of whether
the general practitioner requested C. difficile testing. Using
this design, we aimed to determine the incidence of toxigenic
C. difficile and to characterize patients with CDI. Additionally,
we aimed to evaluate and guide current diagnostic algo-
rithms.
Methods
Study design
The study was set in three medical microbiological laborato-
ries: Stichting Huisartsen Laboratorium (Etten-Leur), the
Laboratory for Medical Microbiology and Immunology of the
St Elisabeth Hospital (Tilburg) and the Laboratory for Clinical
Microbiology and Infectious Diseases of the Isala klinieken
(Zwolle). These laboratories supply microbiological services to
832 general practices with together 2 810 830 patients. All
general practitioners (GPs) were aware the study was being
performed; two GPs declined participation and were not
included in the study. Between 4 October 2010 and 31 January
2012, all unformed stool samples of patients aged ≥2 years,
submitted by GPs, were prospectively tested for the presence
of C. difficile toxin irrespective of whether the GP requested
testing for C. difficile. Samples were excluded when a patient (i)
had a prior positive test or (ii) was tested within the previous
30 days. An unformed stool was defined as ‘taking the shape of
the container’ [14].
Patients with a positive test for C. difficile toxin were
defined as CDI. Using a nested case-control design, patients
with CDI were matched for age (5 years) and sex to two
control patients. Control patients were selected from the
cohort of toxin-negative patients and tested negative at most
1 week before the case patient. If a control patient was not
available at that time, the first patient after the index date (date
of CDI case) was selected. The study protocol was approved
by the LUMC Medical Review Ethics Committee.
Definitions and data collection
We collected basic demographic data of all tested patients.
One laboratory (Etten-Leur) additionally registered whether
the C. difficile test was specifically requested by the GP. This
was used to evaluate whether CDI testing was requested in
current practice.
After obtaining permission of the GP, questionnaires were
sent to CDI patients and sampled controls. We contacted
subjects by mail or telephone to request return of the
questionnaire; this was done up to six times. Questions
focused on medication and contact with infants or healthcare
in the 3 months before diarrhoea, comorbidity in the year
before diarrhoea, travelling history and proximity to other
patients with diarrhoea. Frequency, viscosity and presence of
bloody diarrhoea were ascertained at the height of the
diarrhoeal episode. All variables, except for abdominal pain and
fever, which were deemed too subjective, were included in
univariate analysis. Follow-up of patients with CDI was done
after 6 months by asking the GP about the initiated treatment
for CDI, presence of relapses or death.
Stool examinations
The presence of toxin producing C. difficile was assessed by a
cell cytotoxicity assay in Tilburg, which is still regarded as the
reference standard [15,16]. The two other laboratories used
an enzyme immunoassay (EIA) for toxins A and B (Premier
toxins A&B, Meridian, Bioscience Inc., Cincinnati, OH, USA).
Upon the request of the general practitioner, faeces were
tested for diarrhoeal pathogens other than C. difficile. These
pathogens were tested using local available tests (all PCR).
Testing was possible for: bacterial pathogens (Salmonella spp.,
Shigella spp. and Campylobacter jejuni/coli), parasitic pathogens
(Cryptosporidium, Giardia lamblia and Entamoeba histolytica) or
viruses (norovirus) in all three laboratories. Additional tests
were available upon request or if deemed clinically relevant
based on patient data (data not shown). All microbiological
results, including the result of the C. difficile toxin test, were
reported to the GP.
Stool samples that were positive for C. difficile in the initial
test were cultured and isolates were typed with PCR
ribotyping [17]. When an isolate could not be obtained, a
PCR on the tcdB gene was performed on faeces to confirm the
presence of toxigenic C. difficile [18].
Data analysis
Incidence rates of diarrhoea and intestinal pathogens were
calculated using the total number of person years at risk,
which was calculated by multiplying the general practice
population (the number of people serviced by the participat-
ing general practitioners, according to their patient list) by
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the period of study participation (between 12 and
15 months).
Patients with Clostridium difficile infection and matched
controls were compared using univariate conditional logistic
regression. Results were displayed as matched odds ratios
(mOR) with a 95% confidence interval (95% CI). Subsequently,
all factors with a p-value of <0.10, except for symptoms, were
included in multivariable analysis. Although these variables
were complete in >92% of the CDI patients and controls, we
used multiple imputation to account for missing values in
multivariate analysis. This method is appropriate when
predictors of the missing data are available (missing at random;
MAR) [19]. All potential predictors of missing data, potential
predictors of the outcome and the outcome itself were
included in the imputation procedure. To include the matched
variables (age and gender; both dichotomous) in the multivar-
iate analysis, we performed case-control weighting [20]. This
was possible due to the fact that the case-control study was
nested in a cohort. Weights were determined by prevalence,
age (continuous variable) and sex distribution of patients and
controls compared with the original cohort. In patients,
weights varied only marginally (between 1.2 and 1.4), because
78% of the diagnosed CDI patients participated in the
case-control study. Weights of controls varied between 17
and 112 (mean 41), emphasizing the large sampling fraction and
the relative over-representation of elderly patients due to
matching.
Evaluation of testing strategies
We evaluated the current diagnostic practice of general
practitioners by evaluating the samples for which the GP
requested testing for C. difficile. This method was compared
with the current advice in the Netherlands, the current advice
in the UK and the former advice in the UK. The percentage of
diarrhoeal patients that required testing according to the
aforementioned recommendations, was calculated by using the
prevalence of clinical characteristics in our weighted popula-
tion of diarrhoeal patients and controls (e.g. prevalence of
patients with antibiotic use or prior admission was calculated
because these patients required C. difficile testing according to
current Dutch recommendations). In the population that
required testing, we determined the percentage of CDI (e.g.
among patients with prior antibiotic use or an admission, 8%
were CDI positive). Additionally, we determined the percent-
age of CDI patients that would have been tested by the
algorithm (e.g. 60% of all CDI patients occurred in the group of
patients with prior antibiotic use or an admission).
We used SPSS version 20.0 (SPSS Inc., Chicago, IL, USA) and
STATA software package 10.1 (StataCorp, College Station,
TX, USA) for our analyses.
Results
During the study period, 12 714 unformed stool samples met
the study’s inclusion criteria (Fig. 1). The incidence of
diarrhoea in which investigation of faeces was requested was
44 per 10 000 person years. Patients were on aver-
age 41.3 years old and the majority was female (57.4%)
(Table 1).
Incidence of C. difficile infection
Of 12 714 stool samples, 194 (1.5%) were positive for
C. difficile (incidence of 0.67 per 10 000 patient years). In
Tilburg, a cell cytotoxicity assay (considered as reference
standard) was used to diagnose CDI. Here, 54 tests were
found to be positive among 3009 diarrhoeal samples (1.8%;
103 per 10 000 patient years).
Ninety-nine per cent of the stool samples were also tested
for the presence of pathogens other than C. difficile (12 566/
12 714), which were identified in 21.9% (2786/12 714) of all
samples: in 22.1% of the CDI-negative samples (2763/12 520)
and in 11.8% (23/194) of the CDI-positive samples. The most
frequently found co-pathogen in CDI-positive samples was
Campylobacter coli/jejuni (n = 10; 5%). In total, Campylobacter
coli/jejuni and Giardia lamblia were found in 8.3% (1056/12 714;
3.67 per 10 000 person years) and 3.6% (454/12 714; 1.58
per 10 000 person years) of all samples, respectively.
Salmonella spp. was found in percentages similar to C. difficile:
1.6% (198/12 714; 0.69 per 10 000 person years).
CDI vs controls with diarrhoea
Within the cohort of 12 714 samples, we performed a nested
case-control study. One hundred and fifty-two of 194 CDI
patients (78%) completed the questionnaire and were matched
for age and gender to 304 controls. Participating CDI patients
were on average 52.3 years old (standard deviation 22.5); 61%
of them were female. Symptoms of diarrhoea started in the
community in 94% (n = 143). Three patients (2%) developed
symptoms in a long-term care facility and six (4%) developed
diarrhoea during hospitalization but were diagnosed after
discharge. Compared with controls, CDI patients more often
had severe symptoms (bloody stools, watery or frequent
diarrhoea), underlying diseases, prior hospitalization and prior
use of antibiotics (univariate analysis; Table 2). A third of the
CDI patients (n = 58; 39%) did not use antibiotics nor were
previously hospitalized; 14% of the CDI patients (n = 22) had
no underlying diseases, hospitalization or medication use prior
to diarrhoea. CDI patients reported abdominal pain and fever
in 77% and 31%, respectively; controls reported these
symptoms in 75% and 20%, respectively.
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Six variables had a p-value of <0.10 in univariate analysis and
were possible predictive factors of CDI. These were included
in multivariate analysis together with age and gender. Age
≥50 years, an underlying disease in the year before start of
diarrhoea and hospitalization in the preceding 3 months and
cancer in the preceding year had a strong association with
CDI. Antibiotic use in the preceding 3 months had the
strongest association with CDI (Table 3).
Performance of testing algorithms
According to data from one laboratory (Etten-Leur), general
practitioners request a test for CDI in 7% of submitted
samples (543/8338). These samples included 40% of all
diagnosed CDI patients in this study. Currently, the advice
regarding testing for C. difficile in general practice in the
Netherlands is to test all patients with diarrhoea and recent
antibiotic use or hospitalization. As 18% of the patients in the
study recently used antibiotics or were hospitalized, this
advice would lead to testing of 18% of all diarrhoeal patients,
detecting 61% of all CDI patients. In the United Kingdom, all
diarrhoeal patients aged ≥65 years or patients with recent
antibiotic use or a recent hospitalization are advised to be
tested. Implementing this strategy in our study population
would result in detection of two-thirds of all CDI patients,
whereas it would require testing 31% of all diarrhoeal
samples.
Confirmation of C. difficile
Of the 152 patients with CDI, the presence of C. difficile
could be confirmed by PCR ribotyping or a positive tcdB PCR
in 68% (n = 103). Types 002 and 078 (both n = 11; 11%)
were most frequently found; type 001 (8%), 005 (6%), 014
(8%), 015 (9%) and 126 (4%) were other frequently found
PCR ribotypes. The virulent type 027 that caused many
outbreaks in hospitals [21] was isolated in one patient with
frequent relapses and prior long-term hospitalization. Thir-
ty-five stool samples were not available for confirmation
testing. The majority of the CDI patients in the case-control
study had C. difficile as the only detected pathogen (130 of
152; 86%).
Six months follow-up
Of 122 CDI patients with known follow-up (80.3%), the
majority (n = 96; 78.7%) was treated for the infection:
monotherapy with metronidazole was most frequently used
(n = 85; 88.5%); six patients were treated with vancomycin
(6.3%), three with a combination of both (3.1%). Thirty
patients (24.6%) had recurrent diarrhoea within 6 months,
which was confirmed by a positive toxin test in 36.7%. Within
Samples (N = 12 714)
No. of
cases
% of all
samples
Rate per 10 000
person years (95% CI)
No. of
samples
tested
Female gender 7302 57.4
Age, mean (SD) 41.3 (23.2)
Diagnosed pathogens
Campylobacter coli/jejuni 1056 8.3 3.67 (3.45–3.90) 10 598
Giardia lamblia 454 3.6 1.58 (1.44–1.73) 8954
Salmonella spp. 198 1.6 0.69 (0.60–0.79) 10 598
Clostridium difficile 194 1.5 0.67 (0.58–0.78) 12 714
Shigella spp. 114 0.9 0.40 (0.33–0.47) 10 598
Cryptosporidium 107 0.8 0.37 (0.31–0.45) 8954
Norovirus 75 0.6 0.26 (0.21–0.32) 1374
Entamoeba histolytica 2 0.0 0.01 (0.00–0.02) 6720
Pathogen other than
C. difficile
2786 21.9 9.68 (9.33–10.05) 12 566
All samples were tested for C. difficile, whereas other pathogens were tested upon request of the general practitioner.
All laboratories used a PCR to detect the pathogens: Campylobacter [35,36], Salmonella [36,37], Shigella [38], Giardia
lamblia [39–41], Cryptosporidium [39,40], Entamoeba histolytica [39,40] and Norovirus [42].
TABLE 1. Age, gender and inci-
dence of intestinal pathogens in
unformed stool samples with a test
request from the general practi-
tioner
FIG. 1. Patient inclusion chart.
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6 months, six CDI patients (3.9%) were hospitalized because
of diarrhoea and four died (2.6%). In one patient (0.6%) CDI
contributed to the cause of death.
Discussion
Incidence of CDI in general practice
This study determined the incidence of C. difficile in a large
sample of microbiological test requests from general practi-
tioners. One out of 66 diarrhoeal episodes was positive for
C. difficile (1.5%), which was comparable to the incidence of
Salmonella spp. Earlier studies reported similar incidences of
CDI (1.5–2.1% [4,5]; 0.7–2.5 per 10 000 person years
[2,5,9,22–27]), with the exception of a study from the UK
that reported virtually no CDI in general practice [28]. The
latter UK study confirmed our relatively low rate of salmo-
nellosis (1.8 per 10 000 patient years using faecal culture), but
should be interpreted with caution because exclusion criteria
such as recent travel and diarrhoeal illness lasting over
2 weeks resulted in the analysis of 45% (991/2203) of all
diarrhoeal episodes. Although we included all diarrhoeal
samples that were sent to a laboratory, the incidence of CDI
in our study could be underestimated if diarrhoeal samples of
patients with CDI were not sent to a laboratory and the
disease had a self-limiting course.
Our study included 12 714 diarrhoeal episodes and showed
that CDI is relatively common among diarrhoeal stool samples
and should be included in the differential diagnosis of infectious
diarrhoea in general practice.
When should we consider CDI and request a test?
Dutch GPs are advised to test all patients with prior antibiotic
use or hospitalization for CDI. Currently, GPs do not follow
these recommendations and test only 7% of all diarrhoeal
patients, detecting 40% of all CDI patients. This large
proportion of undiagnosed patients with CDI is in our opinion
undesirable, as all CDI patients had diarrhoeal complaints and
nine patients (5.8%) experienced a complicated course (hos-
TABLE 2. Clinical characteristics of
CDI patients and matched control
patients, analysed with conditional
logistic regression analysis
Characteristics
CDI cases
(N = 152)
Controls
(N = 304) Crude analysis
N % N % mOR 95% CI p-Value
Symptoms
Bloody stools 36 25.2 44 15.7 1.82 1.07–3.09 0.03
Watery diarrhoea 119 78.3 207 68.1 1.71 1.08–2.71 0.02
Frequency of diarrhoea >8 times 68 44.7 75 24.9 2.39 1.59–3.61 <0.01
Time to visit GP <1 month 96 64.5 165 56.3 1.40 0.94–2.10 0.10
Medication
Antibiotics 82 55.0 49 16.6 8.15 4.57–15.5 <0.01
Other medication 92 60.5 166 56.1 1.26 0.81–1.98 0.31
PPI/antacid 43 29.1 60 21.1 1.59 0.99–2.55 0.06
Statin 25 16.9 40 14.1 1.38 0.74–2.58 0.31
NSAID 11 7.4 24 8.4 0.80 0.37–1.73 0.57
DM 10 6.8 19 6.7 1.03 0.46–2.28 0.95
Immunosuppression 11 7.4 12 4.2 1.72 0.74–4.02 0.21
Diuretics, antihypertensives 47 30.9 76 25.2 1.48 0.87–2.53 0.15
Underlying diseases
Any disease 90 59.2 120 39.7 2.64 1.66–4.20 <0.01
Circulatory system diseases 18 11.8 34 11.3 1.09 0.54–2.19 0.81
Respiratory system diseases 24 15.8 26 8.6 1.90 1.08–3.36 0.03
Cancer 10 6.6 7 2.3 3.60 1.21–10.7 0.02
Environment
Previous admission 28 18.4 21 7.0 3.16 1.67–5.99 <0.01
Family member with diarrhoea 7 4.8 23 8.0 0.58 0.25–1.35 0.20
Infant <2 years old 40 27.6 97 32.2 0.75 0.47–1.20 0.23
Visited foreign country
In western world 16 15.4 43 18.4 0.79 0.40–1.56 0.50
Outside western world 15 14.4 41 17.5 0.77 0.38–1.58 0.48
The crude analysis was done by univariate conditional logistic regression, which takes into account the matched factors
‘age’ and ‘gender’. Variables with a p-value <0.10 (n = 9) supplemented with age and sex were included in the
multivariate analysis (Table 3).
TABLE 3. Multivariable analysis using weighted logistic
regression analysis
Factors
MVA
OR 95% CI p-value
Age ≥50 1.41 0.79–2.52 0.25
Gender 1.18 0.70–1.99 0.53
Antibiotics 6.88 3.97–11.9 <0.01
PPI/antacid 1.10 0.56–2.08 0.77
Any disease 1.80 1.00–3.23 0.05
Respiratory system diseases 1.25 0.51–3.06 0.63
Cancer 4.04 1.47–11.1 <0.01
Previous admission 1.66 0.75–3.68 0.21
In the multivariate analysis (MVA) we included all possible predictive factors for
CDI with a p-value of <0.10 according to the crude analysis and ‘age’ and ‘gender’.
Symptoms were not included in the MVA. We adjusted the variables in this table
for age, gender, antibiotics, PPI/antacid, respiratory system diseases, cancer and
previous admission. The variable ‘any disease’ was not adjusted for ‘respiratory
system diseases’ and ‘cancer’ as these variables were included in ‘any disease’.
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pitalization or death within 6 months). A similar course was
observed in community-based studies [5,26]; however, as most
CDI patients in these studies were treated for CDI, we expect
the number of complicated courses to be higher when CDI is
undiagnosed and therefore untreated. In our study, compli-
cated courses were also experienced by patients without
traditional risk factors (3/9; 33.3%), which underlines the
necessity for diagnosis.
Because testing of all unformed stool samples, as was the
former UK advice, requires a large budget, this is currently
probably not achievable in most laboratories and general
practices. Our study confirms that well-known risk factors for
nosocomial CDI (antibiotic use and hospitalization) are
present in only 61% of the patients with CDI in the community.
As shown in multivariate analysis, the clinical presentation of
patients with CDI differs from other causes of diarrhoea, as
they frequently have bloody stools, watery diarrhoea and many
stools daily. Therefore, we suggest including clinical symptoms
in a future prediction model for CDI. For now, we recommend
following current Dutch guidelines or the current UK advice in
the Netherlands. This would result in detection of 61% or 72%
of all CDI, respectively, which would clearly outperform
current practice.
Strengths and weaknesses
We are the first to provide a complete overview of incidence,
clinical characteristics and testing strategies of CDI in general
practitioners’ practice. The size of the cohort and high
participation rate (78%), and the early and thorough follow-up
of the questionnaire, provide a stable base for our conclu-
sions. Furthermore, we were able to confirm C. difficile with
PCR ribotyping in two-thirds of the cases with a positive
toxin test, which enabled us to compare types circulating in
general practice with those causing disease in hospitals.
Similar types were seen in general practice and hospitals in
the Netherlands during the study period [29,30]. As recent
evidence suggests that direct transmission of C. difficile
between hospitalized patients is not the prime route of
transmission [31], the large overlap of PCR ribotypes in both
settings strengthen the hypothesis of movement of C. difficile
between both settings.
Our study also has limitations. Firstly, we restricted our
study to samples that were sent to a laboratory. Our
conclusions are therefore not necessarily generalizable to
settings with different testing criteria. Although Dutch GPs
request laboratory diagnostics in 10–20% of gastroenteritis
consultations [32] and 20–30% of the GPs in the UK request
testing [9,33], testing criteria in other countries could differ.
Secondly, testing strategies in our study include the ‘reference
standard’ and an enzyme immunoassay (EIA), which has a
limited negative and positive predictive value in the commu-
nity [34]. Missing cases due to a false-negative toxin test could
have resulted in an underestimation of the incidence of CDI.
However, the incidence according to the reference standard
(used in Tilburg) was even higher. The large sampling fraction
in the case-control study makes it unlikely that false-negative
patients were included as controls. However, false-positive
cases might have occurred. In the majority of the CDI cases
(n = 130, 86%) no pathogens other than C. difficile were
found. Additionally, in 13 of the 22 CDI cases with a
co-pathogen, the presence of toxigenic C. difficile was con-
firmed by PCR ribotyping. Therefore, we assume that bias
due to to false-positive cases is limited. Thirdly, we would like
to stress that the results of Table 4 are dependent on the
test that was used. In a setting where different tests for
C. difficile are used, sensitivity and specificity and therefore
the measured incidence of CDI (and the weighted case-con-
trol analyses of Table 4) can differ. Nonetheless, our conclu-
sion regarding present insufficient testing and suggestions for
future testing are strong and will hold in a setting with a
different test.
Clinical relevance
Although it has several limitations, our study illustrates that
CDI should be included in the differential diagnosis of
infectious diarrhoea in general practice, even when the patient
was not recently using antibiotics, is young and has no
comorbidity. Additionally, it highlights that current Dutch
testing strategies are insufficient. We recommend following
current Dutch guidelines or the current UK advice in the
Netherlands, which outperform current practice without
testing a large number of samples.
TABLE 4. Performance of seven different algorithms for testing diarrhoeal samples for Clostridium difficile in general practice
Test algorithm for CDI in diarrhoeal
samples from the community Setting
Patients tested Positive results Detection of CDI
% of all unformed
stool samples
% of all tested
samples % of all positives
≥2 years Former advice UK (2009) 100 1.5 100
≥65 years, after AB use or hospitalization Current advice UK (2012) 31 3.5 72
After AB use or hospitalization Current advice NL 18 5.0 61
Doctor’s current practice Current practice NL 7 8.1 40
These percentages are based on the weighted analysis of all CDI patients and controls (n = 12 714). AB, antibiotic.
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